Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Total body irradiation (TBI) can induce lethal myelosuppression, due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologic toxicities of TBI. Here, using selective and structurally distinct small molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, we have demonstrated that selective cellular quiescence increases radioresistance of human cell lines in vitro and mice in vivo. Cell lines dependent on CDK4/6 were resistant to IR and other DNA-damaging agents when treated with CDK4/6 inhibitors. In contrast, CDK4/6 inhibitors did not protect cell lines that proliferated independently of CDK4/6 activity. Treatment of wild-type mice with CDK4/6 inhibitors induced reversible pharmacological quiescence (PQ) of early HSPCs but not most other cycling cells in the bone marrow or other tissues. Selective PQ of HSPCs decreased the hematopoietic toxicity of TBI, even when the CDK4/6 inhibitor was administered several hours after TBI. Moreover, PQ at the time of administration of therapeutic IR to mice harboring autochthonous cancers reduced treatment toxicity without compromising the therapeutic tumor response. These results demonstrate an effective method to mitigate the hematopoietic toxicity of IR in mammals, which may be potentially useful after radiological disaster or as an adjuvant to anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies revealed that CDK4/6 inhibitors protect both cancer cells and normal hematopoietic cells from cytotoxicity induced by IR and DNA damaging agents (125)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [125]
Experimental — accuracy not yet measuredIn the citing paper
“p21 upregulation actually protected HSCs against IR by limiting IR-induced DNA damage and p53 activation and by promoting HSC cell cycle entry and self-renewing expansion, suggesting that p21 and p16 may have opposite effects on IR-induced HSC senescence.46-48”
From Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner (2014) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
The comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,835
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465 · cited 1×
“Prior work in mice has shown that p21CIP, a potent CDK inhibitor and critical mediator of the p53-mediated DNA damage response (29, 30), plays an important role in regulating HSPC quiescence after DNA damage (31).”
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 2×
“PD0332991 (13, 14) was provided by Pfizer Inc.”
BackgroundMethodDi Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Cited by
Items 101–174 of 174
Novel radiosensitizing anticancer therapeutics.
Linkous, A. G., & Yazlovitskaya, E. M. (2012) · PubMed · Cited by 33
Nrf2‐modulation by seleno‐hormetic agents and its potential for radiation protection
Bartolini, D., Tew, K. D., Marinelli, R., Galli, F., & Wang, G. Y. (2019) · BioFactors · doi:10.1002/biof.1578 · Cited by 30
Qi, Y., Chen, S., Lu, Y., Zhang, Z., Wang, S., Chen, N., Shen, M., Chen, F., Chen, M., Quan, Y., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.010 · Cited by 27
Protracted Oxidative Alterations in the Mechanism of Hematopoietic Acute Radiation Syndrome
Gorbunov, N. V., & Sharma, P. (2015) · Antioxidants · doi:10.3390/antiox4010134 · Cited by 26
Kim, J., Jayne, L. A., Bai, Y., Feng, M. J. H. H., Clark, M. A., Chung, S., Christman, J. W., Cianciolo, R. E., & Pabla, N. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113939 · Cited by 26
The regulation of hematopoietic stem cell fate in the context of radiation
Lu, Y., Hu, M., Zhang, Z., Qi, Y., & Wang, J. (2020) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2020.01.002 · Cited by 24
Bolzacchini, E., Pomero, F., Fazio, M., Civitelli, C., Fabro, G., Pellegrino, D., Giordano, M., & Squizzato, A. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.009 · Cited by 21
Dentofacial Parameters Explaining Variability in Retroclination of the Maxillary Central Incisors
Lapatki, B. G., Klatt, A., Schulte‐Mönting, J., & Jonas, I. E. (2007) · Journal of Orofacial Orthopedics / Fortschritte der Kieferorthopädie · doi:10.1007/s00056-007-0637-x · Cited by 27
Does CDKN2A Loss Predict Palbociclib Benefit?
Gao, J. J., Adams, R. P., & Swain, S. M. (2015) · Current Oncology · doi:10.3747/co.22.2700 · Cited by 19
The Effect and Mechanism of Negative Pressure Wound Therapy on Lymphatic Leakage in Rabbits
Yuan, Y., Niu, Y., Xiao, W., Qi, B., Hu, X., & Yu, A. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.09.065 · Cited by 19
CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
Arsenijevic, T., Coulonval, K., Raspé, E., Demols, A., Roger, P. P., & Laethem, J. V. (2023) · Cancers · doi:10.3390/cancers15030968 · Cited by 21
Wang, W., Oh, S., Koester, M., Abramowicz, S., Wang, N., Tall, A. R., & Welch, C. L. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001294 · Cited by 20
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
Chan, I. C. C., Zhang, P., Pan, X., Castro, C., Fox, N., Lewis, A. M., Weis, K., Cuibus, M. A., Tittley, S., Petrone, G. E. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02526-w · Cited by 23
Guan, D., Yang, Y., Pang, M., Liu, X., Li, Y., Huang, P., Shang, H., Wei, H., & Ye, Z. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04732-0 · Cited by 17
Mayer, E. L., DeMichele, A. M., Rugo, H. S., Miller, K. D., Waks, A. G., Come, S., Mulvey, T. M., Jeselsohn, R. M., Overmoyer, B. A., Guo, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz198 · Cited by 17
Xing, S. J., Shen, X., Yang, J., Wang, X., Ou, H., Zhang, X., Xiong, G.-L., Shan, Y., Cong, Y., Luo, Q.-L., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.07.2325 · Cited by 17
Cell-cycle Alterations in Post-mitotic Cells and Cell Death by Mitotic Catastrophe
Lombardi, D., & Lasagni, L. (2016) · InTech eBooks · doi:10.5772/61783 · Cited by 17
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL
Vo, T.-T. T., Lee, J. S., Nguyen, D. M., Lui, B., Pandori, W., Khaw, A., Mallya, S., Lu, M., Müschen, M., Konopleva, M. Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0024 · Cited by 17
Macy, M. E., Mody, R. J., Reid, J. M., Piao, J., Saguilig, L., Alonzo, T. A., Berg, S. L., Fox, E., Weigel, B. J., Hawkins, D. S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po-24-00418 · Cited by 19
Sivina, M., Yamada, T., Park, C. S., Puppi, M., Coşkun, S., Hirschi, K. K., & Lacorazza, H. D. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.224436 · Cited by 15
Transport processes of radiopharmaceuticals and -modulators
Efferth, T., & Langguth, P. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-59 · Cited by 15
Lazo, J. S., Sharlow, E. R., Epperly, M. W., Lira, A. K., Leimgruber, S., Skoda, E. M., Wipf, P., & Greenberger, J. S. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208421 · Cited by 15
Zellefrow, C. D., Sharlow, E. R., Epperly, M. W., Reese, C. E., Shun, T., Lira, A. K., Greenberger, J. S., & Lazo, J. S. (2012) · Radiation Research · doi:10.1667/rr2810.1 · Cited by 14
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.548 · Cited by 14
Guo, L., Hu, Y., Chen, X., Li, Q., Wei, B., & Ma, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1970 · Cited by 14
Tian, J. J., Doi, H., Saar, M., Santos, J., Li, X., Peehl, D. M., & Knox, S. J. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.08.051 · Cited by 14
Chen, J., Gao, X., Yang, L., Fu, W., Liang, L., Li, J., Hu, B., Sun, Z.-J., Huang, S., Zhang, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep26003 · Cited by 14
Sadeghi, H., Bagheri, H., Shekarchi, B., Javadi, A., & Najafi, M. (2019) · Current Drug Research Reviews · doi:10.2174/2589977511666191031094625 · Cited by 11
Preclinical discovery and development of abemaciclib used to treat breast cancer
Wright, M. D., & Abraham, J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1853097 · Cited by 12
Chen, J., Wu, W., He, X., Jia, L., Yang, J., Si, X., Yu, K., Li, S., Qiu, Y., Xu, K., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s332384 · Cited by 8
Resistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Faller, D. V., Castañeda, S. A., Zhou, D., Vedamony, M. M., Newburger, P. E., White, G. L., Kosanke, S. D., Plett, P. A., Orschell, C. M., Boosalis, M. S., et al. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.10.021 · Cited by 8
Self-citationPatel, T. I., Joshi, J. N., Valvezan, A. J., & Moschitto, M. J. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03288-y · Cited by 6
Shi, W., Wang, R., Qian, J., Wang, L., Li, Y., Mi, Y., Jia, Z., Pan, M., Zhang, X., Ye, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02080 · Cited by 6
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
Cyclin-dependent kinase inhibitors: efficacy and safety
Кононенко, И. Б., Снеговой, А. В., & Selchuk, V. Y. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-10-42-55 · Cited by 7
Zhang, C., Cui, X., Liu, Y., Wang, F., Signer, R. A. J., Nattamai, K., Zhou, D., Zheng, Y., Geiger, H., Wan, F., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282028 · Cited by 5
Self-citationZhang, X., Qiao, Z., Guan, B., Wang, F., Shen, X., Shu, H. G., Shan, Y., Cong, Y., Xing, S. J., & Yu, Z.-Y. (2024) · Molecules · doi:10.3390/molecules29040816 · Cited by 6
Dawood, S. S., Chiu, J. W.-Y., Huang, C., Nag, S. M., Sookprasert, A., Yap, Y. S., & Yusof, M. M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1783646 · Cited by 5
Li, C., Horton, J. K., Sale, M. E., Curd, L., Goti, V., Tao, W. X., & Beelen, A. P. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01179-x · Cited by 5
Wang, B., Piccolantonio, A., Altulea, A., Huang, M., Joshi, T., Pagliarin, F., Palma, M. D., Lin, Y., Mackedenski, S. J., Ustyantsev, K., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01168-1 · Cited by 5
Rahman, S. A., Poort, H., Schrag, D., Tung, S. C., Zhou, E. S., Wiley, A., Finkelstein, L. B., Elguenaoui, E., Nolan, M., Mayer, E. L., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae316 · Cited by 4
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer
Safaroghli‐Azar, A., Mekonnen, L. B., Hassankhani, R., Lenjisa, J. L., Basnet, S. K. C., Batayneh, H., Rahaman, M. H., & Wang, S. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01550-7 · Cited by 4
Chu, N., Zhang, L., Wang, J., Gu, X., Ding, Y., Huang, K., Que, L., & He, Q. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01103-9 · Cited by 4
Kumar, D., & Devasagayam, T. P. A. (2011) · InTech eBooks · doi:10.5772/24214 · Cited by 3
Gao, P., Cenatus, S., Zhang, D., Chu, S., Henley, N., Pichette, V., Barrera‐Chimal, J., & Gerarduzzi, C. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00407-6 · Cited by 3
Doucette, K., Lai, C., & Pohlmann, P. R. (2020) · The Breast Journal · doi:10.1111/tbj.13955 · Cited by 2
Radioprotectors and Mitigators: Current Status
Yazlovitskaya, E. M. (2013) · Journal of Bioequivalence & Bioavailability · doi:10.4172/jbb.10000e26 · Cited by 2
HSC senescence upon irradiation
Geiger, H. (2014) · Blood · doi:10.1182/blood-2014-03-563718 · Cited by 2
Radioprotection and Molecular Therapy
Tian, J. J. (2012) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000e107 · Cited by 2
Yang, Y., Zhu, S., Fu, Z., Sun, C., Yang, F., Zeng, T., Hua, Y., Bao, S., Gao, X., Huang, X., et al. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-54 · Cited by 1
Bai, W., Shi, S., Yin, D., Guo, C., Song, H., Hu, Y., Gao, J., Qiu, B., Zhang, X., Bi, L., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1722151 · Cited by 1
Hänel, A., Abdelsalam, A., & Tollis, S. (2025) · iScience · doi:10.1016/j.isci.2025.114291 · Cited by 1
Engineered MSCs enable bone marrow-targeted immunomodulation
Xu, S., Xu, J., Yang, Q., Zeng, J., Zhang, M., Wu, Y., Liu, Z., Wang, Q., You, Q., & Zhang, S. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.03.003 · Cited by 1
Lonial, S., & Gleason, C. L. (2014) · Blood · doi:10.1182/blood-2014-04-565317 · Cited by 1
Therapeutic Modulation of DNA Damage and Repair Mechanisms in Blood Cells
Wang, H., Cai, S., Tonsing-Carter, E. Y., & Karen, E. (2011) · InTech eBooks · doi:10.5772/24261
Elucidating and Pharmacologically Targeting Secondary Injury Cascades following Neural Injury
Lucke-Wold, B. P. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6120
Characterization of p27 in Osteosarcoma
Currier, A. W. (2019) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/9v5v-fj82
(2010) · Nature reviews. Cancer · doi:10.1038/nrc2907
Principles of Radiation Oncology
Connell, P. P., & Weichselbaum, R. R. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm045
The molecular and cellular consequences of AsiDNA™ combined with radiotherapy on healthy tissue
Sesink, A. (2023) · theses.fr (ABES) · doi:10.70675/9c9c5f80z9a52z4360z803cz9131e6e43fd3 · Cited by 1
Novel Small Molecule, UTS-1401, as a Radioprotector for Total-Body Irradiation
Valeriote, F. A., Brown, S. L., Media, J. E., Li, P., Maheshwari, M., & Shaw, J. (2024) · Radiation Research · doi:10.1667/rade-22-00030.1
Zhang, X., Shu, H. G., Shen, X., Ji, A., Shuang, X., Zhang, Y., Xing, S. J., Cong, Y., & Yu, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115295
Role of murine double minute (MDM)-2 in kidney injury and repair
Mulay, S. R. (2013) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15768 · Cited by 1
Implication des espèces réactives de l’oxygène (ROS) dans la radiocarcinogenèse thyroïdienne
Boufraqech, M. (2011) · theses.fr (ABES) · doi:10.70675/df472f7ezd5bdz47e0z8965ze2c43b6cedd3 · Cited by 1
Modulation pharmacologique de la radiosensibilité tumorale des mélanomes par inhibition de MEK
Schick, U. (2015) · theses.fr (ABES) · doi:10.70675/1a19d1c3zf22ez4376zaa08z5a042a357d91
Mimicking mammalian hibernation to lock cancer cells in safe quiescence
Jafari, A., Shams, F., & Khanehzar, E. (2026) · Discover Oncology · doi:10.1007/s12672-026-05420-3 · Cited by 1
Martínez, J. R., Dey, A., McDermott, M., Rudolph, K. L., & MacLean, A. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.26.734844
Prospects for protecting normal tissues during chemotherapy of malignant tumors
Belitsky, G. A., Игоревич, К. К., Fetisov, T. I., Геннадьевна, С. Л., & Геннадиевна, Я. М. (2026) · Advances in molecular oncology · doi:10.17650/2313-805x-2026-13-3-52-67
Metadata
- Authors
- Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., Zhou, D., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Harvard University (US)
- Corresponding author
- Sharpless, Norman E.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-07-01
- Volume
- 120
- Issue
- 7
- Pages
- 2528-2536
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2898594
- OpenAlex
- W1967829518
- Cited by
- 168
- References
- 66
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 16 · 2014: 14 · 2013: 14 · 2012: 7
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5r01ag024379-15)
- National Institute on Aging (R01-AG024379, F30AG034806)
- National Cancer Institute (R01CA122023, R01CA122794, R01CA086860)
- National Institute of General Medical Sciences (GM008581, T32GM008719, T32GM008581)
- National Institute of Allergy and Infectious Diseases (R01AI080421, R01AI077454, R01AI080432)
- National Institute of Environmental Health Sciences (P30ES010126)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- CDK4/6 inhibitors, total body irradiation, hematopoietic stem and progenitor cells, quiescent cells, radioresistance (biology), myelosuppression, ionizing radiation, DNA-damaging agents, bone marrow, autochthonous tumors, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Cell Line, Hematopoietic Stem Cells, Mice, Inbred C3H, Mice, Inbred C57BL, Radiation, Mice, Knockout, Cyclin-Dependent Kinase Inhibitor p18, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.